8-K
filed April 2, 2026, 7:59 PM ET
ticker VTGN
CIK 0001411685
regulatory
confidence high
sentiment negative
materiality 0.40
Vistagen falls below Nasdaq audit committee minimum after director resignation
Vistagen Therapeutics, Inc.
- Ms. Mary Rotunno resigned from the Board effective April 1, 2026, reducing Audit Committee from 3 to 2 members.
- Company notified Nasdaq of non-compliance with Listing Rule 5605(c)(2) requiring at least three audit committee members.
- Nasdaq listing not affected; cure period of up to one year from resignation date to regain compliance.
- Board plans to fill vacancy and return to compliance within the cure period.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001628280-26-023176
- form_type
- 8-K
- ticker
- VTGN
- cik
- 0001411685
- company_name
- Vistagen Therapeutics, Inc.
- filed_at
- 2026-04-02T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:32.251227+00:00
- generated_at
- 2026-05-15T07:49:34.591146+00:00
- sec_items
- ["3.01"]
- event_type
- regulatory
- sentiment
- negative
- materiality_score
- 0.4
- calibrated_materiality_score
- 0.4
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001628280-26-023176
- json_url
- https://secwatch.observer/filing/0001628280-26-023176.json
- markdown_url
- https://secwatch.observer/filing/0001628280-26-023176.md
- text_url
- https://secwatch.observer/filing/0001628280-26-023176.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1411685/000162828026023176/0001628280-26-023176-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1411685/000162828026023176/vtgn-20260401.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
LASE
Laser Photonics receives Nasdaq delisting notice for late Q1 2026 10-Q
Laser Photonics Corp
May 22, 2026, 5:27 PM ET
regulatory
Items 3.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
similar materiality
This filing
April 1, 2026, Vistagen Therapeutics, Inc. (the “ Company ”) notified The Nasdaq Stock Market LLC (“ Nasdaq ”) of its current non-compliance with Nasdaq Listing Rule 5605(c)(2), which requires the Audit Committee of a Nasdaq-listed company to have at least three members from its Board of Directors, each meeting independence and certain other criteria. As disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 18, 2026, Ms. Mary Rotunno resigned from the Company’s Board of Directors (the “ Board ”), effective April 1, 2026 (the “ Resignat
Comparable filing
received a notice from Nasdaq Listing Qualifications
department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that since it had not received the Company’s Form 10-Q
for the period ended March 31, 2026, the Company does not comply with Nasdaq’s Listing Rules for continued listing. Nasdaq stated
that the Company has 60 days to submit a plan to regain compliance with respect to this delinquent report. Nasdaq can grant an exception
to allow the Company to regain compliance up to a maximum of 180 calendar days from the due date of the Initial Delinquent Filing, or
November 16, 2026. A
copy of t
Filing page
SEC filing
INV
Innventure regains Nasdaq compliance after appointing Bruce Brown to Audit Committee
Innventure, Inc.
May 19, 2026, 5:45 PM ET
regulatory
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
similar materiality
This filing
April 1, 2026, Vistagen Therapeutics, Inc. (the “ Company ”) notified The Nasdaq Stock Market LLC (“ Nasdaq ”) of its current non-compliance with Nasdaq Listing Rule 5605(c)(2), which requires the Audit Committee of a Nasdaq-listed company to have at least three members from its Board of Directors, each meeting independence and certain other criteria. As disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 18, 2026, Ms. Mary Rotunno resigned from the Company’s Board of Directors (the “ Board ”), effective April 1, 2026 (the “ Resignat
Comparable filing
April 30, 2026, following the resignation of Daniel Hennessy from the Company’s Board of Directors (the “Board”) and Audit Committee effective April 29, 2026, the Company notified The Nasdaq Stock Market LLC (“Nasdaq”) t
Filing page
SEC filing
MYPS
PLAYSTUDIOS receives Nasdaq Capital Market transfer; second compliance period to Nov 2, 2026
PLAYSTUDIOS, Inc.
May 5, 2026, 7:59 PM ET
regulatory
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
similar materiality
This filing
April 1, 2026, Vistagen Therapeutics, Inc. (the “ Company ”) notified The Nasdaq Stock Market LLC (“ Nasdaq ”) of its current non-compliance with Nasdaq Listing Rule 5605(c)(2), which requires the Audit Committee of a Nasdaq-listed company to have at least three members from its Board of Directors, each meeting independence and certain other criteria. As disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 18, 2026, Ms. Mary Rotunno resigned from the Company’s Board of Directors (the “ Board ”), effective April 1, 2026 (the “ Resignat
Comparable filing
May 5, 2026, Nasdaq staff approved the Company’s application to transfer its listing to the Nasdaq Capital Market. The transfer will become effective at the opening of business on May 6, 2026 (the “Transfer Date”) and wi
Filing page
SEC filing
GREE
Greenidge receives Nasdaq notice for audit committee non-compliance after director resignation
Greenidge Generation Holdings Inc.
May 1, 2026, 7:59 PM ET
regulatory
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
similar materiality
This filing
April 1, 2026, Vistagen Therapeutics, Inc. (the “ Company ”) notified The Nasdaq Stock Market LLC (“ Nasdaq ”) of its current non-compliance with Nasdaq Listing Rule 5605(c)(2), which requires the Audit Committee of a Nasdaq-listed company to have at least three members from its Board of Directors, each meeting independence and certain other criteria. As disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 18, 2026, Ms. Mary Rotunno resigned from the Company’s Board of Directors (the “ Board ”), effective April 1, 2026 (the “ Resignat
Comparable filing
April 29, 2026, the Company received a notice from Nasdaq (the “Notice”) confirming the Company’s non-compliance with Nasdaq Listing Rule 5605(c)(2)(A) as a result of Mr. Fearn’s resignation from the Audit Committee. As
Filing page
SEC filing
ARAI
Arrive AI regains compliance with Nasdaq MVPHS rule; delisting notice closed
Arrive AI Inc.
April 28, 2026, 7:59 PM ET
regulatory
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
similar materiality
This filing
April 1, 2026, Vistagen Therapeutics, Inc. (the “ Company ”) notified The Nasdaq Stock Market LLC (“ Nasdaq ”) of its current non-compliance with Nasdaq Listing Rule 5605(c)(2), which requires the Audit Committee of a Nasdaq-listed company to have at least three members from its Board of Directors, each meeting independence and certain other criteria. As disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 18, 2026, Ms. Mary Rotunno resigned from the Company’s Board of Directors (the “ Board ”), effective April 1, 2026 (the “ Resignat
Comparable filing
March 31, 2026, Arrive AI Inc. (the “ Company ”) received a letter from The Nasdaq Listing Qualifications Department
(the “ Staff ”) indicating that the Company’s common stock had failed to maintain a minimum market valu
Filing page
SEC filing
ISPC
iSpecimen flagged for Nasdaq equity shortfall; equity $814K vs $2.5M minimum
iSpecimen Inc.
June 1, 2026, 5:00 PM ET
regulatory
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
This filing
April 1, 2026, Vistagen Therapeutics, Inc. (the “ Company ”) notified The Nasdaq Stock Market LLC (“ Nasdaq ”) of its current non-compliance with Nasdaq Listing Rule 5605(c)(2), which requires the Audit Committee of a Nasdaq-listed company to have at least three members from its Board of Directors, each meeting independence and certain other criteria. As disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 18, 2026, Ms. Mary Rotunno resigned from the Company’s Board of Directors (the “ Board ”), effective April 1, 2026 (the “ Resignat
Comparable filing
May 29, 2026, iSpecimen Inc. (the “Company”)
received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)
notifying the Company that it no longer complies with Nasdaq Listing Rule 5550(b)(1) (the “Rule”), which requires a minimum
of $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market (the “Capital Market”). As reported in the Company’s Quarterly Report
on Form 10-Q for the period ended March 31, 2026, the Company had stockholders’ equity of $814,038. Nasdaq noted that, as of May
29, 2026, the Company doe
Filing page
SEC filing
GENC
Gencor receives NYSE American delinquency notice for late Q2 2026 10-Q filing
GENCOR INDUSTRIES INC
June 1, 2026, 4:09 PM ET
regulatory
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
This filing
April 1, 2026, Vistagen Therapeutics, Inc. (the “ Company ”) notified The Nasdaq Stock Market LLC (“ Nasdaq ”) of its current non-compliance with Nasdaq Listing Rule 5605(c)(2), which requires the Audit Committee of a Nasdaq-listed company to have at least three members from its Board of Directors, each meeting independence and certain other criteria. As disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 18, 2026, Ms. Mary Rotunno resigned from the Company’s Board of Directors (the “ Board ”), effective April 1, 2026 (the “ Resignat
Comparable filing
May 19, 2026, Gencor Industries, Inc. (the “Company”) received a notice (the “Delinquency Notification”) from NYSE Regulation (the “NYSE”) indicating the Company was not in compliance with the NYSE American LLC (“NYSE American”) continued listing standards as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”) with the Securities and Exchange Commission (“SEC”) prior to May 18, 2026, the end of the extension period provided by Form 12b-25, and as a result was subject to the procedures set forth in Section 1007 of the NY
Filing page
SEC filing
HWH
HWH International receives Nasdaq deficiency notice for equity below $2.5M threshold
HWH International Inc.
May 29, 2026, 5:21 PM ET
regulatory
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
This filing
April 1, 2026, Vistagen Therapeutics, Inc. (the “ Company ”) notified The Nasdaq Stock Market LLC (“ Nasdaq ”) of its current non-compliance with Nasdaq Listing Rule 5605(c)(2), which requires the Audit Committee of a Nasdaq-listed company to have at least three members from its Board of Directors, each meeting independence and certain other criteria. As disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 18, 2026, Ms. Mary Rotunno resigned from the Company’s Board of Directors (the “ Board ”), effective April 1, 2026 (the “ Resignat
Comparable filing
May 29, 2026 HWH International Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications
Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with the minimum stockholders’
equity requirement for continued listing on the Nasdaq Capital Market, under Listing Rule 5550(b)(1) because the Company’s stockholders’
equity of $2,078,220 as reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2026 was below the
required minimum of $2.5 million, and because, as of May 29, 2026, the Company did
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.